Premium
P2–317: In vitro characterization of PIB binding to α–synuclein
Author(s) -
Fodero-Tavoletti Michelle,
Cappai Roberto,
Krause Sabine,
Lippoldt Andrea,
Foster Lisa,
Leone Laura,
Smith David,
McLean Catriona,
Rowe Christopher C.,
Dyrks Thomas,
Masters Colin L.,
Villemagne Victor L.
Publication year - 2006
Publication title -
alzheimer's and dementia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.713
H-Index - 118
eISSN - 1552-5279
pISSN - 1552-5260
DOI - 10.1016/j.jalz.2006.05.1157
Subject(s) - thioflavin , dementia with lewy bodies , in vitro , chemistry , fibril , microbiology and biotechnology , immunohistochemistry , lewy body , alpha synuclein , pathology , biology , parkinson's disease , alzheimer's disease , biochemistry , medicine , dementia , disease
years, 4 women, education 12 years) and 7 age, gender and education matched normal Controls (including 4 non-affected siblings) received complete clinical, neuropsychological, MRI and FDG-PET examinations. Regions of interest (ROIs) including the hippocampus (Hip), the entorhinal cortex (EC), the posterior cingulate cortex (PCC), the inferior parietal lobule (IPL), and the superior temporal gyrus (STG) were drawn bilaterally on the MRI scans of all subjects. The ROIs were used to measure volume loss (atrophy) on MRI, and MRglc from the MRI-coregistered, atrophy corrected PET scans. The whole-brain (WB) MRglc was also examined. Results: All presymptomatic FAD cases were comparable to Controls for neuropsychological measures. On MRI, after correcting for the total intracranial volume, none of the FAD cases showed significant volume reductions in any ROI. Conversely, after correcting for pons MRglc, MRglc reductions were found with PET in FAD as compared to Controls in the WB (13%), bilaterally in the IPL (14-16%) and in the STG (11-12%), and in the left EC (21%), PCC (20%), and Hip (12%) (p .05). Conclusions: These results show that FAD individuals in a presymptomatic stage already show widespread MRglc reductions consistent with the typical AD PET pattern in the absence of structural brain atrophy. These data further suggest that PET MRglc measures may serve as biomarkers in the preclinical diagnosis of AD.